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Guidelines recommend protein phosphatase and tensin homolog (PTEN) immunohistochemistry for diﬀerentiating
between benign endometrial hyperplasia (BEH) and atypical endometrial hyperplasia/endometrioid intraepithelial neo-
plasia (AEH/EIN). However, it is unclear when PTEN expression should be deﬁned as ‘lost’ and thus suggestive of
AEH/EIN. We aimed to determine the optimal immunohistochemical criteria to deﬁne PTEN loss in endometrial
hyperplasia, through a systematic review and meta-analysis of diagnostic accuracy. Electronic databases were searched
for studies assessing immunohistochemical expression of PTEN in both BEH and AEH/EIN specimens. PTEN status
(‘loss’ or ‘presence’) was the index test; histological diagnosis (‘AEH/EIN’ or ‘BEH’) was the reference standard. Accu-
racy was quantiﬁed based on the area under the curve (AUC) on summary receiver operating characteristic (SROC)
curves, for several diﬀerent thresholds of PTEN expression. Eighteen studies with 1362 hyperplasias were included. Six
diﬀerent criteria to deﬁne PTEN loss were assessed. Low diagnostic accuracy was found for complete loss of expression
(AUC = 0.71), presence of any null gland (AUC = 0.63), positive cells <10% (AUC = 0.64), positive cells <50%
(AUC = 0.71) and moderate-to-null intensity (AUC = 0.64). Barely moderate diagnostic accuracy was only found for
the subjective criterion ‘weak-to-null intensity’ (AUC = 0.78). Therefore, the clinical usefulness of PTEN immunohisto-
chemistry in this ﬁeld should be further investigated.
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Endometrial hyperplasia includes two diﬀerent
conditions: benign endometrial hyperplasia (BEH),
which is a proliferation reactive to unopposed action
of estrogens, and atypical endometrial hyperplasia/
endometrioid intraepithelial neoplasia (AEH/EIN),
which is a precancerous lesion (1–3). It is crucial to
diﬀerentiate between these two conditions in order
to adopt an appropriate patient management. BEH
may be managed with observation alone, or with
progestins when symptomatic. On the other hand,
AEH/EIN requires total hysterectomy; in selected
cases, a conservative treatment can be chosen, using
progestins alone or combined with hysteroscopic
resection (4–7).
Histologic examination is considered as the gold
standard for the diﬀerential diagnosis between
AEH/EIN and BEH. However, histologic criteria
appear to be poorly reproducible, and endometrial
specimens may show ambiguous features; further-
more, the evaluation of little biopsies is oftenReceived 6 January 2019. Accepted 11 February 2019
161
APMIS 127: 161–169 © 2019 APMIS. Published by John Wiley & Sons Ltd.
DOI 10.1111/apm.12938
JOURNAL OF PATHOLOGY, 
MICROBIOLOGY AND IMMUNOLOGY
aﬀected by tissue inadequacy and artifact changes
(2, 8, 9).
Several immunohistochemical markers have been
proposed in order to improve the diﬀerential diag-
nosis (2). In this ﬁeld, the tumor suppressor protein
phosphatase and tensin homolog (PTEN) has
played a major role, since PTEN loss of expression
is regarded as the crucial event in endometrial car-
cinogenesis and occurs in an early phase (10, 11).
The 2017 guidelines of the European Society of
Gynaecological Oncology (ESGO) recommend the
use of immunohistochemistry for PTEN to diﬀeren-
tiate AEH/EIN from BEH, not specifying the
immunohistochemical criteria to deﬁne PTEN loss
of expression (12).
However, in our previous study we found that
the accuracy of PTEN loss as immunohistochemical
diagnostic marker of AEH/EIN was low (13, 14).
Anyway, immunohistochemical criteria to deﬁne
loss of PTEN expression are not standardized, and
diﬀerent thresholds of expression have been
adopted in the several studies. This might have
aﬀected the diagnostic accuracy evaluation.
In the current study, we aimed to determine: (i)
the optimal criteria for interpreting PTEN immunos-
taining, by assessing how its diagnostic accuracy for
AEH/EIN changes according to diﬀerent thresholds
of percentage of stained cells and intensity of stain-
ing; (ii) if PTEN immunohistochemistry is inter-
preted following the optimal criteria identiﬁed may
be useful in the common practice.
MATERIALS AND METHODS
Study protocol
This study followed the Preferred Reporting Item for Sys-
tematic Reviews and Meta-Analyses (PRISMA) statement
(15) and the Synthesizing Evidence from Diagnostic Accu-
racy Tests (SEDATE) guideline (16). The protocol deﬁn-
ing methods for collecting, extracting and analyzing data
was designed a priori. All stages were conducted indepen-
dently by two reviewers (AR, AT). Disagreements were
resolved by discussion with a third reviewer (GS).
Search strategy and study selection
Methods of search strategy and study selection have been
described previously (13). In brief, we conducted several
researches using the following electronic databases: MED-
LINE, EMBASE, Web of Sciences, Scopus, Clini-
calTrial.gov, OVID, Cochrane Library and Google
Scholar. A combination of the following text words was
used: ‘endometrial hyperplasia’; ‘endometrial intraepithe-
lial neoplasia’; ‘EIN’; ‘precancer’; ‘premalignant’; ‘precur-
sor’; ‘PTEN’; ‘phosphatase and tensin homolog’;
‘marker’; ‘biomarker’; ‘diagnosis’ ‘immunohistochemistry’;
‘immunohistochemical’. In the current study, the research
was updated to October 2018.
All peer-reviewed retrospective or prospective studies
assessing immunohistochemical expression of PTEN on
histological specimens of AEH/EIN and BEH were
included. Exclusion criteria were: data on PTEN expres-
sion not extractable; no diﬀerentiation between AEH/EIN
and BEH; assessment of only AEH/EIN or only BEH;
case reports and reviews; overlapping patient data with a
study already included.
Risk of bias assessment
Risk of bias within studies was assessed using the revised
Quality Assessment of Diagnostic Accuracy Studies (QUA-
DAS-2) (17). For each study, correctness criteria were
applied to four diﬀerent domains related to the risk of bias:
(i) Patient selection: if the patients were consecutive; (ii)
Index test: if criteria for interpreting PTEN immunostaining
were clearly stated; (iii) Reference standard: if histologic
classiﬁcation was unbiased; (iv) Flow and Timing: if all
patients were assessed with the same index test and the same
reference standard. Authors’ judgments were categorized as
‘low risk’ (the criterion was met), ‘high risk’ (the criterion
was not met) or ‘unclear risk of bias’ (not clear whether or
not the criterion was met).
Data extraction
Data extraction was based on methods from our previous
study (13). For each study, we reported two dichotomous
qualitative variables on 2 9 2 contingency tables:
1. PTEN expression (‘loss’ or ‘normal’), which was the
index test;
2. Histological diagnosis (‘AEH/EIN’ or ‘BEH’), which
was the reference standard.
Data regarding the index test were subdivided into
groups based on the diﬀerent criteria to deﬁne PTEN loss
(positive index test):
1. Complete loss of PTEN expression in the whole lesion;
2. Presence of any PTEN-null gland;
3. Percentage of PTEN-positive cells below several
thresholds;
4. Intensity of PTEN immunostaining lower than nor-
mal.
Data regarding the reference standard were extracted
by using the following criteria:
1. For the studies using the WHO classiﬁcation (1–3),
atypical endometrial hyperplasia (simple or complex)
was considered as ‘AEH/EIN’, and endometrial hyper-
plasia without atypia (simple or complex) was consid-
ered as ‘BEH’;
2. For the studies using the endometrial intraepithelial
neoplasia (EIN) classiﬁcation (2, 3), endometrial
intraepithelial neoplasia was considered as ‘AEH/
EIN’, and benign endometrial hyperplasia was consid-
ered as ‘BEH’;
3. Hyperproliferative conditions caused by unopposed
action of estrogens (e.g., ‘disordered proliferative
endometrium’, ‘persistent proliferative endometrium’)
were included in the ‘BEH’ group, as proposed in the
literature (18), since they constitute a pathologic con-
tinuum with endometrial hyperplasia without atypia
(1, 8).
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AEH/EIN cases with PTEN loss were considered as
true positive, BEH cases with PTEN presence as true neg-
ative, AEH/EIN cases with PTEN presence as false nega-
tive and BEH cases with PTEN loss as false positive.
Data analysis
Sensitivity, speciﬁcity, positive likelihood ratio (LR+),
negative likelihood ratio (LR) and diagnostic odds ratio
(DOR) were calculated for each study and as pooled esti-
mate, and reported graphically on forest plots, with 95%
conﬁdence interval (CI). The random eﬀect model of
DerSimonian and Laird was used to pool values, as rec-
ommended by the SEDATE guidelines (16). Statistical
heterogeneity among studies was quantiﬁed by using the
inconsistency index (I2) statistic: heterogeneity was con-
sidered null for I2 = 0, minimal for I2 < 25%, low for
I2 < 50%, moderate for I2 < 75% and high for
I2 ≥ 75%.
The overall diagnostic accuracy was calculated as area
under the curve (AUC) on summary receiver operating
characteristic (SROC) curves. Diagnostic accuracy was con-
sidered absent for AUC ≤ 0.5, low for 0.5 < AUC ≤ 0.75,
moderate for 0.75 < AUC ≤ 0.9, high for
0.9 < AUC < 0.97 and very high for AUC ≥ 0.97.
Diagnostic accuracy assessment was performed for each
group based on the diﬀerent criteria used to deﬁne PTEN
loss.
The data analysis was performed using Review Man-
ager 5.3 (Copenhagen: The Nordic Cochrane Centre,
Cochrane Collaboration, 2014) and Meta-DiSc version 1.4
(Clinical Biostatistics Unit, Ramon y Cajal Hospital,
Madrid, Spain).
RESULTS
Study selection and characteristics
Eighteen observational studies (10, 19–35) were
included in our review. The whole process of study
selection was previously reported (13). The updated
Table 1. Characteristics of the included studies
Year First author Country Period of
enrollment
Sample
size
Precancer Benign Method to assess
PTEN staining
Thresholds
2000 Mutter (10) USA Not reported 28 21 7 Intensity of staining Negative, weak,
moderate
2001 Mutter (19) USA 1998–2000 76 35 41 Dichotomous Any null gland
2003 Orbo (20) Norway 1980–1991 68 39 29 Dichotomous
(percentage of
stained cells)
10% positive
cells
2005 Baak (21) Norway Not reported 103 21 82 Dichotomous Any null gland
2007 Kapucoglu (22) Turkey Not reported 37 10 27 Dichotomous Complete loss
Norimatsu (23) Japan 1998–2005 70 38 32 Dichotomous Any null gland
2008 Lacey (24) USA 1970–2002 308 73 235 Dichotomous Any null gland
Tantbirojn (25) Thailand 2001–2004 45 20 25 Intensity of staining Negative, weak,
moderate
2009 Abd El-Masqoud
(26)
Egypt Not reported 20 8 12 Dichotomous Complete loss
Sarmadi (27) Iran Not reported 29 8 21 Intensity of staining Negative, weak
Percentage of
stained cells
10%, 50%
2010 Pavlakis (28) Greece Not reported 83 58 25 Dichotomous 20%
Xiong (29) China 2001–2006 83 24 59 Percentage of
stained cells
Complete loss,
50%
2011 Pieczynska (30) Poland 1994–2001 132 16 116 Dichotomous Complete loss
Rao (31) India 2005–2007 76 13 63 Intensity of staining Negative, weak,
moderate
Number of null glands Any, 2, 3, 4, 5
or more
Percentage of
stained cells
10%, 50%
2012 Lee (32) S. Korea 1991–2005 42 21 21 Percentage of
stained cells
5%, 95%
Upson (33) USA 1985–2005 112 40 72 Dichotomous 75%
2013 Huang (34) USA Not reported 24 22 2 Dichotomous
(percentage of
stained cells)
10%
2014 Shawana (35) Pakistan 2006–2010 26 6 20 Intensity of staining Negative, weak,
moderate
Total hyperplasias – – 1362 473 889 – –
© 2019 APMIS. Published by John Wiley & Sons Ltd 163
USE OF PTEN IN ENDOMETRIAL HYPERPLASIA
research (May 2018 to November 2018) did not
reveal further eligible studies.
A total of 1362 endometrial hyperplasia speci-
mens were assessed, out of which 473 were classi-
ﬁed as AEH/EIN and 889 were classiﬁed as BEH.
Eleven studies dichotomized PTEN expression, four
studies graded PTEN expression based on the per-
centage of stained cells and ﬁve based on the inten-
sity of immunostaining (Table 1).
Risk of bias assessment
Results of risk of bias assessment are shown in
Fig. S1.
For the ‘patient selection’ domain, three studies
were classiﬁed at unclear risk of bias, since they fol-
lowed a case-control design; all the remaining stud-
ies were considered at low risk.
For the ‘index test’ domain, all studies were con-
sidered at low risk of bias, since criteria used to
deﬁne PTEN loss were detailed enough to be suit-
able for the meta-analysis.
For the ‘reference standard’ domain, ﬁve studies
were classiﬁed at unclear risk of bias, since they did
not specify if histological slides were reviewed to
conﬁrm the diagnosis of benignity or premalig-
nancy.
For the ‘ﬂow and timing’ domain, all studies
were considered at low risk of bias, since in each
study every specimen underwent both the same
index test and the same reference standard.
Diagnostic accuracy assessment
Complete loss of PTEN expression
A complete loss of PTEN expression was used to
deﬁne PTEN loss in eight studies. Pooled sensitivity
and speciﬁcity were 0.41 (95% CI, 0.32–0.50) and
0.90 (95%CI, 0.86–0.93) with moderate and high
heterogeneity (I2 = 71.1% and 83.9%), respectively.
Pooled LR+ and LR were 2.62 (95% CI, 1.46–
4.72) and 0.74 (95% CI, 0.59–0.94), with low and
moderate heterogeneity (I2 = 26.8% and 65.4%),
respectively. Pooled DOR was 4.34 (95%CI, 1.99–
9.47), with low heterogeneity (I2 = 22.4%). The
overall diagnostic accuracy was low, with an AUC of
0.71 (Fig. S2).
Presence of any PTEN-null gland
The presence of any PTEN-null gland was used to
deﬁne PTEN loss in ﬁve studies. Pooled sensitivity
and speciﬁcity were 0.57 (95% CI, 0.50–0.65) and
0.55 (95%CI, 0.50–0.59) with high heterogeneity
(I2 = 83.3% and 89.9%), respectively. Pooled LR+
and LR were1.38 (95% CI, 1.18–1.60) and 0.74
(95% CI, 0.62–0.87), with minimal and moderate
heterogeneity (I2 = 18.7% and 65.4%), respectively.
Pooled DOR was 2.10 (95% CI, 1.40–3.17) with
minimal heterogeneity (I2 = 7.1%). The overall diag-
nostic accuracy was low, with an AUC of 0.63
(Fig. S3).
Percentage of stained cells
Several thresholds of PTEN expression in terms of
percentage of stained cells were used to deﬁne PTEN
loss. Unfortunately, thresholds of 5%, 20%, 75%
and 95% PTEN-positive cells were assessed only in
one study each, not allowing a meta-analysis.
On the other hand, thresholds of expression to
deﬁne PTEN loss suitable for meta-analysis were
<10% (considered in four studies) and <50% (con-
sidered in three studies) of cells positive for PTEN.
Pooled sensitivity and speciﬁcity of the 10%
threshold were 0.37 (95% CI, 0.26–0.48) and 0.91
(95% CI, 0.85–0.96) with low heterogeneity
(I2 = 35.7% and 36.3%). Pooled LR+ and LR
were 3.40 (95% CI, 1.69–6.88) and 0.75 (95% CI,
0.63–0.90) with null heterogeneity (I2 = 0%),
respectively. Pooled DOR was 4.75 (95% CI, 1.95–
11.59) with null heterogeneity (I2 = 0%). The
Table 2. Summary of diagnostic accuracy metrics for all criteria assessed
Complete loss of
expression
Any null gland 10% positive
cells
50% positive
cells
Weak-to-null
expression
Moderate-to-null
expression
Sensitivity 0.41 (0.32–0.50) 0.57 (0.50–0.65) 0.37 (0.26–0.48) 0.69 (0.53–0.82) 0.69 (0.57–0.80) 0.92 (0.82–0.97)
Speciﬁcity 0.90 (0.86–0.93) 0.55 (0.50–0.59) 0.91 (0.85–0.96) 0.59 (0.51–0.68) 0.76 (0.68–0.83) 0.39 (0.30–0.49)
Positive
likelihood
ratio
2.62 (1.46–4.72) 1.38 (1.18–1.60) 3.40 (1.69–6.88) 1.75 (1.35–2.27) 1.90 (1.39–2.59) 1.21 (0.95–1.53)
Negative
likelihood
ratio
0.74 (0.59–0.94) 0.74 (0.62–0.87) 0.75 (0.63–0.90) 0.53 (0.34–0.83) 0.40 (0.12–1.38) 0.38 (0.11–1.29)
Diagnostic
odds ratio
4.34 (1.99–9.74) 2.10 (1.40–3.17) 4.75 (1.95–11.59) 3.71 (1.74–7.90) 6.66 (2.47–17.97) 3.57 (1.09–11.69)
Area under
the curve
0.7055 (low) 0.6289 (low) 0.6427 (low) 0.7143 (low) 0.7823 (moderate) 0.6400 (low)
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overall diagnostic accuracy was low, with an AUC
of 0.64 (Fig. S4).
For the 50% threshold, pooled sensitivity and
speciﬁcity were 0.69 (95% CI, 0.53–0.82) and 0.59
(95%CI) with minimal heterogeneity (I2 = 12.9%
and 36.3%), respectively. Pooled LR+ and LR
were 1.75 (95% CI, 1.35–2.27) and 0.53 (95% CI,
0.34–0.83) with null heterogeneity (I2 = 0), respec-
tively. Pooled DOR was 3.71 (95%CI, 1.74–7.90)
with null heterogeneity (I2 = 0). The overall diag-
nostic accuracy was low, with an AUC of 0.71
(Fig. S5).
Intensity of immunostaining
Based on the intensity of PTEN immunostaining,
criteria to deﬁne PTEN loss suitable for meta-ana-
lysis were ‘weak-to-null expression’ (in ﬁve studies)
and ‘moderate-to-null expression’ (in four studies).
For weak-to-null expression, pooled sensitivity
and speciﬁcity were 0.69 (95% CI, 0.57–0.80) and
0.76 (95% CI, 0.68–0.83) with high heterogeneity
(I2 = 89.5% and 92.3%), respectively. LR+ and
LR were 1.90 (95% CI, 1.39–2.59) and 0.40 (95%
CI, 0.12–1.38) with minimal and high heterogeneity
(I2 = 5.3% and 88.5%), respectively. Pooled DOR
was 6.66 (95% CI, 2.47–17.97) with null hetero-
geneity (I2 = 0%). The overall diagnostic accuracy
was moderate, with an AUC of 0.78 (Fig. S6).
For moderate-to-null expression, pooled sensitiv-
ity and speciﬁcity were 0.92 (95% CI, 0.82–0.97)
and 0.39 (95% CI, 0.30–0.49) with high heterogene-
ity (I2 = 82.5% and 89.7%), respectively. LR+ and
LR were 1.21 (95% CI, 0.95–1.53) and 0.38 (95%
CI, 0.11–1.29) with moderate and low heterogeneity
(I2 = 52.6% and 29.9%), respectively. Pooled DOR
was 3.57 (95% CI, 1.09–11.69) with low hetero-
geneity (I2 = 11.8%). The overall diagnostic accu-
racy was low, with an AUC of 0.64 (Fig. S7).
Diagnostic accuracy metrics for all immunohisto-
chemical criteria evaluated are summarized in
Table 2.
DISCUSSION
Main findings and interpretation
Among the diﬀerent criteria used to deﬁne PTEN
loss in AEH/EIN, only the criterion of weak-to-null
expression based on the intensity of PTEN immunos-
taining showed moderate accuracy in the diﬀerential
diagnosis between BEH and EH/EIN. A complete
loss of PTEN expression, the presence of any PTEN-
null gland and thresholds based on the percentage of
stained cells showed low accuracy instead.
The diagnosis of endometrial hyperplasia is a
well-described problem (2). Although several histo-
logic classiﬁcations have been proposed, the
reproducibility still appears suboptimal (9). The
main problem is in diﬀerentiating between BEH
and AEH/EIN (1, 3, 36); furthermore, some benign
conditions (endometrial polyps, secretory phase,
metaplastic changes) and artifactual changes may
mimic AEH/EIN (3, 8, 9). For this purpose, the
2016 ESMO-ESGO-ESTRO consensus conference
has recommended the use of immunohistochemistry
for PTEN to recognize AEH/EIN (37); such recom-
mendation has been conﬁrmed in the 2017 ESGO
guidelines (12). However, information about its
accuracy was lacking, as well as criteria to use for
its interpretation.
In our previous study, we assessed the diagnostic
accuracy of immunohistochemistry for PTEN in
the diﬀerential diagnosis between AEH/EIN and
BEH. We found that the diagnostic accuracy was
low, regardless of the histologic classiﬁcation sys-
tem used (13). However, we pointed out the lack of
standardized criteria to interpret PTEN immunohis-
tochemistry. In fact, diﬀerent criteria to deﬁne
‘PTEN loss’ were proposed by several authors,
ranging from a single PTEN-null gland to a wide
and complete loss of expression. Furthermore, there
are two crucial parameters that should be consid-
ered: the percentage of stained cells and the inten-
sity of immunostaining.
In the current study, we aimed to deﬁne which
are the optimal criteria for the interpretation of
PTEN immunohistochemistry in endometrial hyper-
plasia. We found that six diﬀerent criteria to deﬁne
PTEN loss were suitable for our meta-analysis: a
complete loss of expression, the presence of any
null gland, two thresholds based on the percentage
of stained cells (<10% and <50%) and two criteria
based on the intensity of staining (‘weak-to-null
expression’ and ‘moderate-to-null expression’).
Considering a complete loss of PTEN expression,
we found good speciﬁcity (0.90), but very low sensi-
tivity (0.40), with a low overall accuracy (0.71).
This ﬁnding suggests that a complete loss of PTEN
expression occurs in only 40% of AEH/EIN. On
the other hand, a complete loss of PTEN expres-
sion might be observed in 10% of BEH, and BEH
is much more common than AEH/EIN. Therefore,
such criterion might often be misleading. Consis-
tently with our results, a study by Ylmaz et al.
found a loss of PTEN expression in several poly-
clonal endometrial specimens (38).
The presence of any null gland appeared as the
least accurate criterion, with low sensitivity (0.57),
low speciﬁcity (0.55) and low overall accuracy
(0.63). Such results are consistent with the possibil-
ity of PTEN-null gland with benign appearance,
which tend to spontaneously regress (39). There-
fore, the presence of only one PTEN-null gland
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should not be considered as a marker of endome-
trial precancer.
With regard to the percentage of stained cells, we
assessed two thresholds to deﬁne PTEN loss: <10%
and <50% of PTEN-positive cells. The values
found for the <10% threshold were similar to those
found for a complete loss (sensitivity = 0.37 vs
0.40; speciﬁcity = 0.91 vs 0.90) with low accuracy
(AUC = 0.64), suggesting that the two criteria are
basically superimposable. Using the <50% thresh-
old, the sensitivity was higher and the speciﬁcity
was lower, as it could be expected from a less strin-
gent criterion; however, the overall accuracy was
still low (AUC = 0.71).
The only one criterion that achieved moderate
diagnostic accuracy (AUC = 0.78) was ‘weak-to-
null expression of PTEN’, based on the intensity of
immunostaining, with a sensitivity of 0.69 and a
speciﬁcity of 0.76. In fact, even when most cells are
PTEN-positive, the immunostaining might be much
lighter than the normal strong staining, indicating
an important decrease of PTEN expression. In
order to establish if PTEN expression is actually
deﬁcient, such criterion would require comparison
with normal endometrium as internal positive con-
trol. In fact, it has been shown than PTEN
immunostaining might appear slightly even in
benign endometrium (40). In that case, correlation
with glandular morphology is indispensable.
Instead, a moderate intensity of PTEN immunos-
taining, which could be interpreted as a slight
decrease of PTEN expression, did not appear as a
reliable criterion to deﬁne PTEN loss, based on the
low accuracy found.
Nonetheless, also the highest AUC value found
slightly exceeded the cut-oﬀ to consider AUC as
moderate. Several other markers have shown an
accuracy higher than that of PTEN in diﬀerentiating
between AEH/EIN and BEH (40, 41). Moreover,
contrary to other markers, PTEN seems not to be
informative about the responsiveness of endometrial
hyperplasia to progestin therapy (41–45), and
appears only weakly associated with the status of its
encoding gene (38, 46). In this regard, the actual
clinical usefulness of PTEN immunohistochemistry
in endometrial hyperplasia appears limited.
As PTEN loss is a crucial and early event in
endometrioid carcinogenesis (10), a possible useful-
ness of PTEN as a support marker and combined
with other markers might be considered. However,
in order to avoid misinterpretations, its immunohis-
tochemical pattern needs to be strictly correlated to
the whole histomorphologic setting, with particular
regard to glandular cyto-architecture and compar-
ison with normal endometrium.
Further studies are necessary to deﬁne whether a
more elaborate scoring system of PTEN immuno-
histochemistry (combining together percentage of
stained cells and intensity of expression) may be
clinically useful, and whether PTEN may have a
role in a panel of immunohistochemical markers.
Strengths and limitations
To the best of our knowledge, our study may be
the ﬁrst meta-analysis assessing the best criteria to
deﬁne PTEN loss and their actual usefulness in dif-
ferentiating BEH and AEH/EIN. We followed a
thorough methodology to assess the accuracy of the
diﬀerent thresholds of PTEN expression.
However, some limitation to our results should
be taken into account. A limitation to our index
test may lie in the subjectivity of the evaluation of
intensity of staining, which may be reliable only if
compared to an internal positive control. Nonethe-
less, it has been suggested that subjective scoring of
PTEN immunohistochemistry is highly reproducible
(47).
On the other hand, the reliability of the reference
standard may be aﬀected by the low reproducibility
of histologic criteria for diﬀerentiating between
BEH and AEH/EIN (9).
Moreover, we were unable to assess the accuracy
of immunohistochemical scores that combine per-
centage of stained cells and intensity of staining. In
this regard, a marked decrease of PTEN expression
in >10% of cancer cells has been used as a reliable
scoring system in prostate cancer (48).
CONCLUSION
Among diﬀerent criteria used to deﬁne PTEN loss
in diﬀerentiating BEH and AEH/EIN., the only
one that showed moderate diagnostic accuracy was
‘weak-to-null expression’, based on the subjective
assessment of the intensity of immunostaining.
Other criteria, including complete loss of expres-
sion, presence of any null gland and percentage of
stained cells, showed low accuracy instead. How-
ever, even with optimized criteria, PTEN loss
appears barely a moderately accurate marker of
premalignant hyperplasia. Therefore, its usefulness
in the common practice should be further investi-
gated.
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Fig. S1. a) Assessment of risk of bias. Summary of
risk of bias for each study; Plus sign: low risk of
bias; minus sign: high risk of bias; question mark:
unclear risk of bias. b) Risk of bias graph about
each risk of bias item presented as percentages
across all included studies.
Fig. S2. Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using a
complete loss of PTEN expression as positive index
test.
Fig. S3. Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
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immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using
the presence of any PTEN-null glands as positive
index test.
Fig. S4. Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using a
percentage of PTEN-positive glands <10% as posi-
tive index test.
Fig. S5 Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using a
percentage of PTEN-positive glands <50% as posi-
tive index test.
Fig. S6 Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using
weak-to-null expression of PTEN as positive index
test.
Fig. S7 Forest plots of individual studies and
pooled sensitivity, speciﬁcity, positive and negative
likelihood ratio and diagnostic odds ratio of PTEN
immunohistochemical assessment in diﬀerential
diagnosis between benign and premalignant
endometrial hyperplasia, with SROC curve, using
moderate-to-null expression of PTEN as positive
index test.
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